Barbara Ferstl

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Andréas Mackensen, John B.A.G. Haanen, Christian Koenecke et al. · Nature Medicine · 2023 · 218 citations · Full text

Cancer Immunosurveillance, Cldn6-specific Car-t Cells, T Cells +15

Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1 <i>Nef</i>-Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption

Ellen G. Harrer, Michael Bäuerle, Barbara Ferstl et al. · Antiviral Therapy · 2005 · 103 citations · Full text

Vaccination, Therapeutic Vaccination, Human Retrovirus +14

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Marc S. Raab, Monika Engelhardt, Antje Blank et al. · The Lancet Haematology · 2020 · 77 citations

Hematological Malignancy, Phase 1–2A, Medicine +6

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong, Noffar Bar, Laura París et al. · Blood · 2022 · 67 citations

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

K. Elias, Uta Bertsch, Ema Požek et al. · Journal of Clinical Oncology · 2024 · 48 citations · Full text